Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE) to Ring The Nasdaq Stock Market Opening Bell
July 18 2016 - 9:00AM
What:Aeglea BioTherapeutics, Inc.
(“Aeglea”) (Nasdaq:AGLE), a biotechnology company committed to
developing enzyme-based therapeutics in the field of amino acid
metabolism to treat rare diseases and cancer, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, David G. Lowe, Ph.D.,
Co-Founder, President & CEO, will ring the Opening
Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Tuesday, July 19, 2016 – 9:15 a.m. to 9:30
a.m. ET
Aeglea Media Contact:Kelly
Boothe415-946-1076kboothe@brewlife.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About AegleaAeglea is a biotechnology company
committed to developing enzyme-based therapeutics in the field of
amino acid metabolism to treat rare diseases and cancer. The
company’s engineered human enzymes are designed to degrade specific
amino acids in the blood in order to reduce toxic levels of amino
acids in inborn errors of metabolism or to exploit the dependence
of certain cancers on specific amino acids. In addition to the
ongoing Phase 1 clinical trial in patients with solid tumors in its
lead product candidate AEB1102, Aeglea holds effective U.S. INDs
for trials of AEB1102 in patients with Arginase I deficiency and in
cancer patients with hematological malignancies. The company is
building a pipeline of additional product candidates targeting key
amino acids, including AEB4104, which degrades homocystine, a
target for an inborn error of metabolism, as well as two potential
treatments for cancer, AEB3103, which degrades cysteine/cystine,
and AEB2109, which degrades methionine. For more information, visit
http://aegleabio.com.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables
customers to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 70 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
more than 3,700 listed companies with a market value of
approximately $9.3 trillion and nearly 17,000 corporate clients. To
learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2024 to May 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From May 2023 to May 2024